Moberg Pharma AB announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma's new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28th 2023. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden.

Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to follow during upcoming months and timelines may vary between countries.